Systemic Sunitinib Malate Treatment for Advanced Juxtapapillary Retinal Hemangioblastomas Associated with von Hippel-Lindau Disease.

ABSTRACT:

Purpose

To describe the clinical course of advanced juxtapapillary retinal capillary hemangioblastomas (RCH) associated with von Hippel-Lindau (VHL) disease treated with systemic sunitinib malate, an agent that inhibits both anti-vascular endothelial growth factor and anti-platelet-derived growth factor signaling.

Design

Observational case review.

Participants

Three patients with advanced VHL-related juxtapapillary RCH treated with systemic sunitinib malate.

Methods

Patient 1 was followed routinely every 4 months while on systemic sunitinib prescribed by her oncologist for metastatic pancreatic neuroendocrine and kidney tumors. Patients 2 and 3 were part of a prospective clinical trial evaluating the use of systemic sunitinib for ocular VHL lesions during a per

SUBMITTER: Knickelbein JE 

PROVIDER: S-EPMC5490440 | biostudies-literature | 2017 May-Jun

REPOSITORIES: biostudies-literature